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from approximately 2.5 million patients. Data was extracted for insulin naïve and 
prior insulin T2D patients initiated on basal insulin as monotherapy or as part of a 
basal-bolus regimen in 2004–2006. RESULTS: The study included 7209 new basal 
insulin users, of which 4792 (67%) were insulin naive. Overall, 4728 (66%) used 
analogues, with similar proportions using monotherapy (67%) and basal-bolus 
therapy (65%). The proportion of analogue users was greater among prior insulin 
users: 541 of 619 (87%) for monotherapy and 1331 of 1798 (74%) for basal-bolus 
therapy compared with 2258 of 3702 (61%) and 598 of 1090 (55%) among naïve 
users. Monotherapy for naïve patients was initiated mainly by the GP (NPH 70%, 
analogue 59%), for prior users mainly by the internist (NPH 49%, analogue 59%)%), 
same as for basal-bolus users (NPH 67–68%, analogue 75–80%). With NPH, 22% 
discontinued their prescription (average of 220 days) and with basal analogues 17% 
(average of 230 days). Furthermore, 6% of patients on NPH and 11% with basal 
analogues added-on to their prescription (after an average of 119 days and 126 days, 
respectively). Only 17% of patients switched treatment with basal analogues com-
pared with NPH (average of 190 days) versus 32% (average of 158 days), respectively. 
CONCLUSIONS: When new insulin treatment is initiated, analogues are more often 
prescribed than NPH, more frequently prescribed by Dutch internists and not discon-
tinued or switched as frequently as NPH, indicating that basal insulin analogues give 
a more sustained and satisfactory result.
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OBJECTIVES: Many aspects of the scientiﬁc, economic and political discussions on 
the beneﬁt of new medicines, for which modern insulins are a pivotal example, inﬂu-
ence recent decisions about drug reimbursement. This study was undertaken to 
compare the reimbursement status of long acting insulin analogues (LAIA) in several 
industrialized countries around the globe, where different criteria for public funding 
of pharmaceuticals have been used, but all include estimates of clinical effectiveness 
and/or cost effectiveness. METHODS: The study was performed based on a combina-
tion of desk research, direct contact with national diabetes stakeholders and expert 
review, using a pre-deﬁned questionnaire. In the ﬁrst phase, information was gathered 
from each country on diabetes prevalence, cost, relevant policies and guidelines through 
a range of sources including government and patient association websites, published 
scientiﬁc literature, media reports. In the second phase additional information about 
reimbursement status of LAIA was sought from recommendations obtained from the 
websites of HTA or similar agencies, or interviews carried out with national stakehold-
ers representing health ministries, patient organisations or medical community. 
RESULTS: Fifteen countries have been included in the study (Australia, New Zealand, 
Canada, UK, The Netherlands, France, Germany, Austria, Sweden, Norway, Latvia. 
Lithuania, Estonia, Hungary, Bulgaria). Only in France LAIA are reimbursed in 65%, 
in all remained countries—in 100%. But in most countries there are several restrictions 
on access to LAIA, namely criteria for this type of treatment have been developed to 
respond the clinical and economic evidence (use in selected patients, application only 
from a relevant specialist, regular reassessments of metabolic control, listing after the 
company agreed to a price reduction). CONCLUSIONS: The story of LAIA is impor-
tant not only because of the way the evidence has been interpreted, but because the 
voice of consultative bodies resulted in action by the health care purchasers.
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OBJECTIVES: The aim of this study was to collect comparable and reliable data about 
consumption of drugs for treatment of diabetes mellitus in Slovakia during the period 
1999–2008. METHODS: Data of wholesalers (following ATC/DDD), who are legally 
obliged provide this information to the Slovak Institute for Drug Control, was used 
for the analysis. The results were expressed in the numbers of the packages, ﬁnance 
units (a) and deﬁned daily doses per 1000 inhabitants per day (DID). RESULTS: The 
collected data shows a signiﬁcant increases in the antidiabetic’s consumption from 
1999 to 2008 in term of DID (in 1999 (33.34) and in 2008 (48.63)). A moderate 
increase in A10AB group (Insulins and analogues, fast-acting) in 1999 (3.03), in 2003 
(3.47) and in 2008 (5.25), a signiﬁcant decrease in A10AC group (Insulins and ana-
logues, intermediate-acting) in 1999 (4.79), in 2003 (3.94) and in 2008 (2.20), a 
moderate increase in A10AD (Insulins and analogues, intermediate-acting combin.) in 
1999 (2.47), in 2003 (2.71) and in 2008 (4.05), a noticeable increase in A10AE 
(Insulins and analogues, long-acting) in 1999 (0.05), in 2003 (0.02) and in 2008 
(1.99), a dramatic increase in A10BA (Biguanides) in 1999 (4.82), in 2003 (7.66) and 
in 2008 (13.51), a relatively stable consumption in A10BB (Sulfonamides) in 1999 
(17.57), in 2003 (15.87) and in 2008 (19.29) and a moderate increase in A10BD 
(Biguanides and sulfonamides in combination) in 1999 (0.52), in 2003 (0.95) and in 
2008 (1.68) in term of DID can be seen from this analysis. Financial expenditures for 
antidiabetics were in 1999 (a19,271,000) and in 2008 (a38,952,000). CONCLU-
SIONS: Inseparable components of the Slovak drug policy must be viewed realistically 
with regard to the antidiabetics’ consumption. Adherence to principles of diabetes 
mellitus treatment’s guidelines lead to fundamental short and long term ﬁnancial 
savings within health care systems.
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OBJECTIVES: Exenatide and glargine are used for the treatment of type 2 diabetes 
(T2D) patients who are inadequately controlled on oral antidiabetic (OAD) medica-
tions. This study examined concomitant medications (including “off- label” use), 
resource utilization, and mean HbA1C (A1C) reduction after initiation of exenatide 
compared to glargine. METHODS: A retrospective claims analysis comprised of adult 
patients with T2D who initiated exenatide (N  9264) or glargine (N  3791) therapy 
between April 1, 2005 and June 30, 2007. Concomitant medications and resource 
utilization were estimated using logistic regression with propensity score stratiﬁcation 
used to control for baseline patient characteristics. A subgroup analysis was performed 
in patients who had baseline and follow-up A1C data for exenatide (n  606) and 
glargine (n  251) to examine mean A1C reduction. RESULTS: A higher percentage 
of exenatide-treated patients were using concomitant metformin only (21.4% vs. 
10.7%, p  0.0001) and a lower percentage were using concomitant sulfonylurea only 
(3.2% vs. 6.4%, p  0.001). There was no signiﬁcant differences between percentage 
of patients using at least 1 OAD medication (89.2% vs. 88.9%, p  0.14) in both 
cohorts. Exenatide-treated patients had 26% lower risk of hospitalizations (OR: 0.74, 
p  0.0001) mainly due to 38% lower risk of macrovascular complications (OR: 0.62, 
p  0.001). Exenatide-treated patients also experienced 22% lower risk of hypoglyce-
mic events (OR: 0.78, p  0.037). A higher percentage of exenatide-treated patients 
with a baseline A1C q 7% achieved an A1C goal of  7 (36.3% vs. 19.3%, p  0.001). 
Exenatide-treated patients experienced a signiﬁcantly greater mean reduction in A1C 
compared to glargine-treated patients after adjusting for baseline A1C (0.80 vs. 
0.52, p  0.0142). CONCLUSIONS: Most patients were concomitantly using some 
OAD medications in both cohorts. Exenatide-treated patients had a signiﬁcantly lower 
risk of hospitalizations, macrovascular complications and hypoglycemic events. In the 
patient subset with A1C data, exenatide-treated patients had a signiﬁcantly greater 
reduction in mean A1C and higher percentage achieving goal than glargine-treated 
patients.
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OBJECTIVES: Clinical evidence evaluating polypharmacy and health care utilization 
with the use of continuous subcutaneous insulin infusion (CSII) in persons with 
uncontrolled Type 2 diabetes is limited. This study provides a real-world (retrospec-
tive) evaluation of the impact of CSII among 973 patients with Type 2 diabetes initiat-
ing CSII therapy between January 2005–October 2007 (mean age 48 years, 47% male, 
mean duration of follow-up 17 months). We hypothesized that CSII therapy would 
reduce rates of polypharmacy (multiple diabetes medication use), ER visits, and hos-
pitalizations. METHODS: Administrative claims from a large, geographically diverse, 
US health plan were used. RESULTS: More than 1/3 of subjects taking oral anti-dia-
betic medications (OADs) before CSII initiation discontinued oral therapy altogether 
once they began CSII. The mean number of OADs used by subjects decreased by 0.67 
OADs (1.45 OADs before vs. 0.78 OADs after, p  0.001) after CSII initiation. The 
number of subjects using multiple OADs decreased by 58% (40% before vs. 17% 
after, p  0.001) and rates of switching or augmenting oral therapy decreased from 
44% to 25% (p  0.001) from baseline to follow-up. The rate of ambulatory visits 
increased from pre- to post-CSII initiation (1.80 visits/subject/month before vs. 2.01 
visits/subject/month after CSII initiation, p  0.01), likely reﬂecting increased use of 
diabetes education services related to CSII. However, the rates of ER visits (0.11 
visits/subject/month before vs. 0.08 visits/subject/month after, p  0.01) and hospital-
izations (0.03 visits/subject/month before vs. 0.01 visits/subject/month after, p  0.01) 
signiﬁcantly decreased after CSII initiation. CONCLUSIONS: Insulin pump therapy 
(CSII) was associated with signiﬁcant decreases in polypharmacy and medication 
changes. Also, CSII may lead to a reduction in health care utilization as indicated by 
reductions in rates of ER visits and hospitalizations.
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Diabetes is one of the most prevalent diseases of 21st century. In Greece, according to 
IDF, 737.700 people were suffering from diabetes in 2006 with prevalence rate 8.6% 
of the adult population. The Greek NHS decides reimbursement level based on disease. 
Nevertheless a paradox that exists in Diabetes case is that insulins are fully reimbursed 
whereas oral medications are reimbursed 75%. Moreover, the blood glucose measur-
ing tapes are distributed for free in patients taking insulin, contrary to patients in 
oral medications that have to pay the whole amount. OBJECTIVES: To assess the 
